2024/09/05
Boston, MA, United States, September 5, 2024 — Antennova, a clinical-stage biotech company focused on oncology, today announced that its parent company, Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK), will participate in the H.C. Wainwright 26th Annual Global Investment Conference. Antengene will showcase its latest R&D advancements during a featured Fireside Chat.
Fireside Chat:
September 10th, 2024 (Tuesday), 4:30 pm – 5:00 pm (US Eastern Time)
Location: Holmes I – 4th Floor, Lotte New York Palace Hotel
Webcasting Link for the Fireside Chat:
https://journey.ct.events/view/48a63922-9bbf-487b-8152-bf12ba2f890e
1×1 Meetings:
September 9th to 11th, 2024 (Monday to Wednesday)
Location: Lotte New York Palace Hotel
About Antennova
Antennova, a Delaware corporation and a subsidiary of Antengene (HKEX: 6996), is a clinical-stage biotech company specialized in developing innovative therapeutics that target the critical biological mechanisms that enable cancers to evade and resist treatment by current drugs. Antennova is developing a pipeline of oncology candidates that can potentially enhance the effectiveness of standard therapies, reverse checkpoint inhibitor (CPI) resistance, and target “cold tumors” that are not responsive to the current CPI therapies.
Antennova has achieved significant milestones which include advancing and developing 4 clinical stage programs: ATN-031: anti-CD24 monoclonal antibody; ATN-037: CD73 orally administered small molecule inhibitor; ATN-022: Claudin 18.2 ADC; and ATN-101: anti-PD-L1/4-1BB bispecific antibody. The U.S. Food and Drug Administration (FDA) has awarded Orphan Drug Designations to ATN-022, for gastric and pancreatic cancers, and to ATN-101, for pancreatic cancer.
Forward-Looking Statements
The forward-looking statements made in this document relate only to the events or information as of the date on which the statements are made in this document. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this document completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this document, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this document. Any of these intentions may alter in light of future development.
